computer‐generated randomization scheme (Teva)
90
Structured Review
Teva
computer‐generated randomization scheme
Computer‐Generated Randomization Scheme, supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+randomization+scheme/randomisation+scheme/pmc10765473-1492-11-17
Average 90 stars, based on 1 article reviews
Computer‐Generated Randomization Scheme, supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+randomization+scheme/randomisation+scheme/pmc10765473-1492-11-17
Average 90 stars, based on 1 article reviews
computer‐generated randomization scheme - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Sequencing:Article Title: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis Article Snippet: .. Teva retains the right to delete confidential information and to object to suggest publication and/or its timing (at the Company’s sole discretion) If Teva chooses to publish this study a copy will be provided to the investigator at least 30 days prior to the expected date of submission to the intended publisher (trial.gov) Risk of bias Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “The Article Title: Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " The computer‐generated Article Title: GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Article Snippet: .. The computerized Article Title: Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " The computer‐generated Selection:Article Title: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis Article Snippet: .. Teva retains the right to delete confidential information and to object to suggest publication and/or its timing (at the Company’s sole discretion) If Teva chooses to publish this study a copy will be provided to the investigator at least 30 days prior to the expected date of submission to the intended publisher (trial.gov) Risk of bias Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “The Article Title: Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " The computer‐generated Article Title: Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " The computer‐generated Produced:Article Title: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis Article Snippet: .. Teva retains the right to delete confidential information and to object to suggest publication and/or its timing (at the Company’s sole discretion) If Teva chooses to publish this study a copy will be provided to the investigator at least 30 days prior to the expected date of submission to the intended publisher (trial.gov) Risk of bias Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “The Article Title: Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Article Snippet: Methods In this randomised, double-blind trial, undertaken in 80 sites in 16 countries, 481 patients presenting with a clinically isolated syndrome with unifocal manifestation, and two or more T2-weighted brain lesions measuring 6 mm or more, were randomly assigned to receive either subcutaneous glatiramer acetate 20 mg per day (n=243) or placebo (n=238) for up to 36 months, unless they converted to clinically defi nite multiple sclerosis.. The randomisation scheme used SAS-based blocks stratifi ed by centre, and patients and all personnel were masked to treatment assignment.. The primary endpoint was time to clinically defi nite multiple sclerosis, based on a second clinical attack. other:Article Title: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Article Snippet: Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “The computer-generated randomization scheme prepared by the Generated:Article Title: GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Article Snippet: .. The computerized |